| In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. | |
| | |
MedLine Citation:
|
PMID: 20209060 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([Gly(A21)]insulin) and M2 ([Gly(A21),des-Thr(B30)]insulin). The aim of this study was to characterize the glargine metabolites in vitro with regard to their insulin receptor (IR) and IGF-1 receptor (IGF1R) binding and signaling properties as well as their metabolic and mitogenic activities. METHODS: The affinity of human insulin, insulin glargine and its metabolites to the IR isoforms A and B or IGF1R was analyzed in a competitive binding assay using SPA technology. Receptor autophosphorylation activities were studied via In-Cell Western in CHO and MEF cells overexpressing human IR-A and IR-B or IGF1R, respectively. The metabolic response of the insulins was studied as stimulation of lipid synthesis using primary rat adipocytes. Thymidine incorporation in Saos-2 cells was used to characterize the mitogenic activity. CONCLUSIONS: The binding of insulin glargine and its metabolites M1 and M2 to the IR were similar and correlated well with their corresponding autophosphorylation and metabolic activities in vitro. No differences were found towards the two IR isoforms A or B. Insulin glargine showed a higher affinity for IGF1R than insulin, resulting in a lower EC(50) value for autophosphorylation of the receptor and a more potent stimulation of thymidine incorporation in Saos-2 cells. In contrast, the metabolites M1 and M2 were significantly less active in binding to and activation of the IGF1R and their mitogenicity in Saos-2 cells was equal to human insulin. These findings strongly support the idea that insulin glargine metabolites contribute with the same potency as insulin glargine to blood glucose control but lead to significantly reduced growth-promoting activity. |
| | |
Authors:
|
Mark R Sommerfeld; Günter Müller; Georg Tschank; Gerhard Seipke; Paul Habermann; Roland Kurrle; Norbert Tennagels |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-03-04 |
Journal Detail:
|
Title: PloS one Volume: 5 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-03-08 Completed Date: 2011-01-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States |
Other Details:
|
Languages: eng Pagination: e9540 Citation Subset: IM |
Affiliation:
|
Research and Development TD Metabolism, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipocytes
/
cytology Animals CHO Cells Cricetinae Cricetulus Fibroblasts / metabolism Humans Insulin / analogs & derivatives*, metabolism* Mice Phosphorylation Rats Receptor, IGF Type 1 / metabolism Receptor, Insulin / metabolism Signal Transduction* |
| Chemical | |
Reg. No./Substance:
|
0/glargine; 11061-68-0/Insulin; EC 2.7.10.1/Receptor, IGF Type 1; EC 2.7.10.1/Receptor, Insulin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, ...
Next Document: Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice.